SOLID DOSAGE FORMS WITH IMPROVED DISINTEGRATION PROFILES
Methods and compositions related to improved solid dosage forms (e.g., minitablets) that facilitate the oral delivery of bacteria or agents of bacterial origin are provided herein.
1 . A solid dosage form of a pharmaceutical composition comprising a pharmaceutical agent and one or more disintegrating agents, wherein the total mass of the one or more disintegrating agents is at least 5% of the total mass of the pharmaceutical composition and wherein the pharmaceutical agent comprises bacteria and/or microbial extracellular vesicles (mEVs).
2 . The solid dosage form of claim 1 , wherein the one or more disintegrating agents comprises L-HPC.
3 . The solid dosage form of claim 2 , wherein the L-HPC is L-HPC of grade LH-11.
4 . The solid dosage form of claim 2 or 3 , wherein the total L-HPC mass is at least 0.1% and no more than 10% of the total mass of the pharmaceutical composition.
5 . The solid dosage form of any one of claims 1 to 4 , wherein the one or more disintegrating agents comprises crospovidone.
6 . The solid dosage form of claim 5 , wherein the total crospovidone mass is at least 1% and no more than 15% of the total mass of the pharmaceutical composition.
7 . The solid dosage form of any one of claims 1 to 6 , wherein the total pharmaceutical agent mass is at least 0.5% and no more than 75% of the total mass of the pharmaceutical composition.
8 . A solid dosage form of a pharmaceutical composition comprising:
a pharmaceutical agent having a total pharmaceutical agent mass that is at least 0.5% and no more than 75% of the total mass of the pharmaceutical composition, wherein the pharmaceutical agent comprises bacteria and/or microbial extracellular vesicles (mEVs); lowsubstituted hydroxypropyl cellulose (L-HPC) having a total L-HPC mass that is at least 0.1% and no more than 10% of the total mass of the pharmaceutical composition;
and crospovidone having a total crospovidone mass that is at least 1% and no more than 15% of the total mass of the pharmaceutical composition.
9 . The solid dosage form of claim 8 , wherein the total L-HPC mass plus the total crospovidone mass is at least 5% of the total mass of the pharmaceutical composition.
10 . The solid dosage form of claim 8 , wherein the total L-HPC mass plus the total crospovidone mass is at least 10% of the total mass of the pharmaceutical composition.
11 . The solid dosage form of any one of claims 8 to 10 , wherein the L-HPC is L-HPC of grade LH-11.
12 . The solid dosage form of any one of claims 8 to 11 , wherein the total L-HPC mass is at least 0.3% and no more than 7% of the total mass of the pharmaceutical composition; the total crospovidone mass is at least 5% and no more than 10% of the total mass of the pharmaceutical composition.
13 . The solid dosage form of any one of claims 8 to 12 , wherein the total L-HPC mass is at least 0.4% and no more than 6% of the total mass of the pharmaceutical composition; the total crospovidone mass is at least 6% and no more than 8% of the total mass of the pharmaceutical composition.
14 . The solid dosage form of any one of claims 8 to 13 , wherein the total L-HPC mass is at least 0.5% and no more than 5% of the total mass of the pharmaceutical composition; the total crospovidone mass is about 7% of the total mass of the pharmaceutical composition.
15 . The solid dosage form of any one of claims 1 to 13 , wherein the total pharmaceutical agent mass is at least 1.2% and no more than 75% of the total mass of the pharmaceutical composition.
16 . The solid dosage form of any one of claims 1 to 13 , wherein the total pharmaceutical agent mass is at least 1.4% and no more than 65% of the total mass of the pharmaceutical composition.
17 . The solid dosage form of any one of claims 1 to 13 , wherein the total pharmaceutical agent mass is at least 1.5% and no more than 63% of the total mass of the pharmaceutical composition.
18 . The solid dosage form of any one of claims 1 to 13 , wherein the total pharmaceutical agent mass is at least 1.6% and no more than 60% of the total mass of the pharmaceutical composition.
19 . The solid dosage form of any one of claims 1 to 18 , further comprising mannitol having a total mannitol mass that is at least 25% and no more than 95% of the total mass of the pharmaceutical composition.
20 . The solid dosage form of any one of claims 1 to 19 , further comprising magnesium stearate having a total magnesium stearate mass that is at least 0.01% and no more than 10% of the total mass of the pharmaceutical composition.
21 . The solid dosage form of any one of claims 1 to 20 , further comprising colloidal silicon dioxide having a total colloidal silicon dioxide mass that is at least 0.01% and no more than 10% of the total mass of the pharmaceutical composition.
22 . The solid dosage form of claim 21 , wherein the total pharmaceutical agent mass is at least 5% and no more than 25% of the total mass of the pharmaceutical composition; the total mannitol mass is at least 61% and no more than 80.5% of the total mass of the pharmaceutical composition; the total L-HPC mass is about 5% of the total mass of the pharmaceutical composition; the total crospovidone mass is about 7% of the total mass of the pharmaceutical composition; the total magnesium stearate mass is at least 1.5% and no more than 2% of the total mass of the pharmaceutical composition; and the total colloidal silicon dioxide mass is about 0.5% of the total mass of the pharmaceutical composition.
23 . The solid dosage form of claim 21 , wherein the total pharmaceutical agent mass is at least 5% and no more than 60% of the total mass of the pharmaceutical composition; the total mannitol mass is at least 26.5% and no more than 81.5% of the total mass of the pharmaceutical composition; the total L-HPC mass is about 5% of the total mass of the pharmaceutical composition; the total crospovidone mass is 7% of the total mass of the pharmaceutical composition; the total magnesium stearate mass is at least 1% and no more than 1.5% of the total mass of the pharmaceutical composition; and the total colloidal silicon dioxide mass is about 0.5% of the total mass of the pharmaceutical composition.
24 . The solid dosage form of claim 21 , wherein the total pharmaceutical agent mass is at least 3% and no more than 50% of the total mass of the pharmaceutical composition; the total mannitol mass is at least 36.5% and no more than 84.9% of the total mass of the pharmaceutical composition; the total L-HPC mass is about 5% of the total mass of the pharmaceutical composition; the total crospovidone mass is 7% of the total mass of the pharmaceutical composition; the total magnesium stearate mass is at least 1% and no more than 1.5% of the total mass of the pharmaceutical composition; and the total colloidal silicon dioxide mass is about 0.5% of the total mass of the pharmaceutical composition.
25 . The solid dosage form of claim 21 , wherein the total pharmaceutical agent mass is at least 10% and no more than 50% of the total mass of the pharmaceutical composition; the total mannitol mass is at least 56.5% and no more than 76% of the total mass of the pharmaceutical composition; the total L-HPC mass is about 5% of the total mass of the pharmaceutical composition; the total crospovidone mass is about 7% of the total mass of the pharmaceutical composition; the total magnesium stearate mass is at least 1% and no more than 1.5% of the total mass of the pharmaceutical composition; and the total colloidal silicon dioxide mass is about 0.5% of the total mass of the pharmaceutical composition.
26 . The solid dosage form of claim 21 , wherein the total pharmaceutical agent mass is about 50% of the total mass of the pharmaceutical composition; the total mannitol mass is about 36.5% of the total mass of the pharmaceutical composition; the total L-HPC mass is about 5% of the total mass of the pharmaceutical composition; the total crospovidone mass is about 7% of the total mass of the pharmaceutical composition; the total magnesium stearate mass is about 1% of the total mass of the pharmaceutical composition; and the total colloidal silicon dioxide mass is about 0.5% of the total mass of the pharmaceutical composition.
27 . The solid dosage form of claim 21 , wherein the total pharmaceutical agent mass is at least 5% and no more than 60% of the total mass of the pharmaceutical composition; the total mannitol mass is at least 26% and no more than 81% of the total mass of the pharmaceutical composition; the total L-HPC mass is about 5% of the total mass of the pharmaceutical composition; the total crospovidone mass is about 7% of the total mass of the pharmaceutical composition; the total magnesium stearate mass is about 1.5% of the total mass of the pharmaceutical composition; and the total colloidal silicon dioxide mass is about 0.5% of the total mass of the pharmaceutical composition.
28 . The solid dosage form of claim 21 , wherein the total pharmaceutical agent mass is about 0.5% of the total mass of the pharmaceutical composition; the total mannitol mass is about 90.5% of the total mass of the pharmaceutical composition; the total crospovidone mass is about 7% of the total mass of the pharmaceutical composition; the total magnesium stearate mass is about 1% of the total mass of the pharmaceutical composition; and the total colloidal silicon dioxide mass is about 1% of the total mass of the pharmaceutical composition.
29 . The solid dosage form of claim 21 , wherein the total pharmaceutical agent mass is about 5% of the total mass of the pharmaceutical composition; the total mannitol mass is about 86% of the total mass of the pharmaceutical composition; the total crospovidone mass is about 7% of the total mass of the pharmaceutical composition; the total magnesium stearate mass is about 1% of the total mass of the pharmaceutical composition; and the total colloidal silicon dioxide mass is about 1% of the total mass of the pharmaceutical composition.
30 . The solid dosage form of claim 21 , wherein the total pharmaceutical agent mass is about 25% of the total mass of the pharmaceutical composition; the total mannitol mass is about 66% of the total mass of the pharmaceutical composition; the total crospovidone mass is about 7% of the total mass of the pharmaceutical composition; the total magnesium stearate mass is about 1% of the total mass of the pharmaceutical composition; and the total colloidal silicon dioxide mass is about 1% of the total mass of the pharmaceutical composition.
31 . The solid dosage form of any one of claims 1 to 30 , wherein the pharmaceutical agent comprises bacteria.
32 . The solid dosage form of claim 31 , wherein the bacteria are lyophilized bacteria.
33 . The solid dosage form of claim 31 or 32 , wherein the bacteria are of the genus Lactococcus , Prevotella , Bifidobacterium , or Veillonella .
34 . The solid dosage form of claim 31 or 32 , wherein the bacteria are of the species Lactococcus lactis cremoris .
35 . The solid dosage form of claim 34 , wherein the Lactococcus lactis cremoris is Lactococcus lactis cremoris Strain A (ATCC designation number PTA-125368).
36 . The solid dosage form of claim 31 or 32 , wherein the bacteria are of the species Veillonella parvula .
37 . The solid dosage form of claim 36 , wherein the Veillonella parvula is Veillonella parvula (ATCC designation number PTA-125691).
38 . The solid dosage form of claim 31 or 32 , wherein the bacteria are of the species Prevotella histicola .
39 . The solid dosage form of claim 38 , wherein the Prevotella histicola is Prevotella histicola Strain B 50329 (NRRL, accession number B 50329).
40 . The solid dosage form of claim 31 or 32 , wherein the bacteria are of the species Bifidobacterium animalis .
41 . The solid dosage form of claim 40 , wherein the Bifidobacterium animalis is Bifidobacterium animalis ssp. lactis (ATCC designation number PTA-125097).
42 . The solid dosage form of claim 31 or 32 , wherein the bacteria are a species listed in Table 1, Table 2, or Table 3.
43 . The solid dosage form of claim 31 or 32 , wherein the bacteria are a bacterial strain that has at least 95% genomic, 16S ribosomal ribonucleic acid, or clustered regularly interspaced short palindromic repeats sequence identity with a strain listed in Table 1 or Table 3.
44 . The solid dosage form of claim 31 or 32 , wherein the bacteria are a bacterial strain that has at least 99% genomic, 16S ribosomal ribonucleic acid, or clustered regularly interspaced short palindromic repeats sequence identity with a strain listed in Table 1 or Table 3.
45 . The solid dosage form of claim 31 or 32 , wherein the bacteria are a bacterial strain listed in Table 1 or Table 3.
46 . The solid dosage form of any one of claims 31 to 45 , wherein the bacterial are live, attenuated, or dead.
47 . The solid dosage form of any one of claims 1 to 30 , wherein the pharmaceutical agent comprises mEVs.
48 . The solid dosage form of claim 47 , wherein the mEVs are isolated mEVs.
49 . The solid dosage form of claim 47 , wherein the mEVs are secreted mEVs.
50 . The solid dosage form of claim 47 , wherein the mEVs are processed mEVs.
51 . The solid dosage form of any one of claims 1 to 50 , wherein the solid dosage form is a minitablet.
52 . The solid dosage form of claim 50 , wherein the minitablet is a 1 mm minitablet, 1.5 mm minitablet, 2 mm minitablet, 3 mm minitablet, or 4 mm minitablet.
53 . The solid dosage form of claim 51 or 52 , wherein a plurality of minitablets are contained in a capsule.
54 . The solid dosage form of any one of claims 1 to 53 , further comprising an enteric coating.
55 . The solid dosage form of claim 54 , wherein the enteric coating is a single enteric coating or more than one enteric coating.
56 . The solid dosage form of claim 54 or 55 , wherein the enteric coating comprises an inner enteric coating and an outer enteric coating, and wherein the inner and outer enteric coatings are not identical.
57 . The solid dosage form of claim any one of claims 54 to 56 , wherein the enteric coating comprises a methacrylic acid ethyl acrylate (MAE) copolymer (1:1).
58 . The solid dosage form of any one of claims 54 to 57 , wherein the enteric coating comprises cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), poly(vinyl acetate phthalate) (PVAP), hydroxypropyl methylcellulose phthalate (HPMCP), a fatty acid, a wax, shellac (esters of aleurtic acid), a plastic, a plant fiber, zein, Aqua-Zein (an aqueous zein formulation containing no alcohol), amylose starch, a starch derivative, a dextrin, a methyl acrylate-methacrylic acid copolymer, cellulose acetate succinate, hydroxypropyl methyl cellulose acetate succinate (hypromellose acetate succinate), a methyl methacrylate-methacrylic acid copolymer, or sodium alginate.
59 . The solid dosage form of any one of claims 54 to 57 , wherein the enteric coating comprises an anionic polymeric material.
60 . A method of preventing or treating a disease of a subject, the method comprising administering to the subject a solid dosage form of any one of claims 1 to 59 .
61 . Use of a solid dosage form of any one of claims 1 to 59 for the treatment or prevention of a disease of a subject.
62 . Use of a solid dosage form of any one of claims 1 to 59 for the preparation of a medicament for treating or preventing a disease in a subject.
63 . A solid dosage form of any one of claims 1 to 59 for use in the treatment or prevention of disease of a subject.
64 . A method of preparing a solid dosage form of a pharmaceutical composition, the method comprising:
(a) combining into a pharmaceutical composition:
(i) a pharmaceutical agent having a total pharmaceutical agent mass that is at least 1% and no more than 75% of the total mass of the pharmaceutical composition, wherein the pharmaceutical agent comprises bacteria and/or microbial extracellular vesicles (mEVs);
(ii) low-substituted hydroxypropyl cellulose (L-HPC) having a total L-HPC mass that is at least 0.1% and no more than 10% of the total mass of the pharmaceutical composition;
(iii) crospovidone having a total crospovidone mass that is at least 1% and no more than 15% of the total mass of the pharmaceutical composition; and
(b) compressing the pharmaceutical composition into a solid dosage form.
65 . A method of preparing a solid dosage form of a pharmaceutical composition, the method comprising:
(a) combining into a pharmaceutical composition:
(i) a pharmaceutical agent having a total pharmaceutical agent mass that is at least 1% and no more than 75% of the total mass of the pharmaceutical composition, wherein the pharmaceutical agent comprises bacteria and/or microbial extracellular vesicles (mEVs);
(ii) crospovidone having a total crospovidone mass that is at least 1% and no more than 15% of the total mass of the pharmaceutical composition; and
(b) compressing the pharmaceutical composition into a solid dosage form.
66 . The method of claim 64 or 65 , further comprising the step of enterically coating the solid dosage form to obtain an enterically coated solid dosage form.
67 . The method of any one of claims 64 to 66 , wherein the solid dosage form is a minitablet.